Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, Double-blind, Parallel-group, Placebo-controlled Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor

Trial Profile

Randomised, Double-blind, Parallel-group, Placebo-controlled Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idalopirdine (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms STARBRIGHT
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 04 May 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
    • 09 Jan 2018 Results of pooled data from three trial (NCT01955161, NCT02006641 and NCT02006654) assessing whether idalopirdine is effective for symptomatic treatment of mild to moderate AD, were published in the JAMA: the Journal of the American Medical Association.
    • 20 Jul 2017 Results (n=2525) from STAR Phase III Program (NCT01955161, NCT02006641, NCT02006654), presented at the Alzheimer's Association International Conference 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top